The Allevi Liver dECM promises the fabrication of liver tissue that has a more representative physiological function. The product uses a combination of a type I collagen Allevi bioink for patterning as well as Xylyx Bio’s highly desired liver-specific TissueSpec® ECM to enhance specialized biological response.
Xylyx Bio products for cell culture are obtained from porcine or human tissue sources and processed to various formats, enabling cell culture models that are significantly more predictive of physiology. Their 3D TissueSpec® ECM hydrogels and scaffolds provide support to cell culture models, facilitating the acceleration of drug discovery, development and tissue regeneration.
“We are thrilled to partner with Allevi and share our expertise in tissue-specific ECM,” stated Andrea Nye, Chief Executive Officer at Xylyx Bio. “Recognizing the importance of the native cellular microenvironment, Xylyx Bio harnesses the body’s innate biology in the form of tissue-specific extracellular matrix. By sourcing extracellular matrix from native organs and tissues, Xylyx produces tissue-specific substrates that comprise both the mechanical properties and complex ratios of ECM components specific and unique to each tissue and organ type.”
Founded in 2014, Allevi claims that its “mission is to provide users the ability to design, engineer, and manufacture 3D tissue.” To deliver important building blocks and provide users with the best experience possible to drive new scientific discoveries, Allevi is hopeful that the new dECM bioink will provide scientists a revolutionary approach that allows scientists to print 3D tissue structures with biochemical and mechanical features inherent in human physiology.
[Images: Allevi and Xylyx Bio]
Xylyx Bio’s Co-founder and Chief Strategy Officer, John O’Neil, added that a “deeper understanding of the comprehensive nature of tissues and cells and their interaction with the cellular microenvironment – that is, the extracellular matrix – holds great promise to lead to a paradigm shift in 3D bioprinting, allowing researchers to study physiologic activity of cells in vitro towards a better understanding of disease and development of more effective drugs and treatments.”
You May Also Like
SmarTech Patent Reports Provide New Insights into Corporate Strengths and Strategies
SmarTech Analysis’ range of reports on patents in the Additive Manufacturing (AM) sector provides unique tools for better understanding the strengths and weaknesses of individual firms and going well beyond...
3D Printed Visual Aids for the Courtroom
I’ve been following the developments in 3D printing for the courts closely for years. We’ve seen how 3D scanners and VR can be used in the courts, how Canadian company...
Thesis Student Creates Business Case for Desktop 3D Printing E-Cigarette Cases
Thesis student Calvin Smith, at Minnesota State University, brings up a topic most 3D printing enthusiasts and users should be interested in as he explores the limits—and endless possibilities— of...
3D Printing News Briefs: March 23, 2019
We’ve got plenty of business news to share in this week’s 3D Printing News Briefs, but first we’ll start off with something fun – the winners have been announced for...
View our broad assortment of in house and third party products.